Interview with Julianna Lisziewicz, President, Genetic Immunity
Genetic Immunity has been founded in 1998. What drove you to set up the company at that time? J.L: To understand the context better, I first need to give a…
Address: Berlini str. 47-49, H-1045Budapest,Hungary
Tel: +36 1 272 0364
Web: http://www.geneticimmunity.com/GI00.html
Genetic Immunity is a privately held US/Hungarian clinical-stage biotechnology company focusing on the discovery, development and commercialization of a new class of immunotherapeutic biologics (‘Immune Therapies’ or ‘Therapeutic Vaccines’) for the treatment of chronic viral infections, cancer and allergy. Our Immune Therapies are designed to intensify or boost specific immune responses to modify or control these presently incurable diseases. We believe that our Products will allow people to live a better and longer life.
Our proprietary Immune Therapy Platform Technology includes the plasmid DNA-based antigen design, nanomedicine formulation and topical administration targeting antigens to dendritic cells. Our technologies support the rapid and cost-effective development of original biologic Products for several indications and provide tools for the selection of an optimal treatment for every patient based on his disease and genetic background.
Our lead Product candidate for the treatment of HIV/AIDS, referred to as ‘DermaVir’, is a therapeutic HIV vaccine effective in boosting immune responses that kill HIV-infected cells. Our Phase I and Phase II clinical trials demonstrated boosting of HIV-specific T cells and specific killing of HIV-infected cells that are not eliminated by current antiretroviral drugs. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. The goal of DermaVir immune intensification is to modify HIV disease, decrease antiretroviral drug exposure while maintaining undetectable HIV-RNA levels and achieve a remission (functional cure) in HIV-infected patients.
Our pipeline product candidate with animal proof of concept, for the treatment of Chlamydia infection, is referred to as ‘ChlamyDerm’ and our allergen-specific immunotherapy is referred to as ‘DermAll’. ChlamyDerm decreased the amount of infected cells together with infection-associated inflammation in mice experiments. DermAll decreased the allergic symptoms by balancing allergen-specific immune responses in mice experiments. Other pipeline candidates for virus-associated cancers and warts are in discovery phase.
There are four principal components that comprise our comprehensive Immune Therapy platform technology which are designed to work in conjunction to treat and/or control chronic infectious diseases, cancer and allergy, as follows:
1.Our Active Pharmaceutical Ingredients (API):
We have been designing (ANTIGENeering) our APIs to be specific, safe and effective. It consists of a single plasmid DNA (pDNA) immunogen ANTIGENeered to express several antigens, to contain molecular safety features and to release Virus Like Particles (VLP+) in the body of the patients. API with these crucial properties is not feasible with protein or peptide antigens.
2.Nanomedicine – our Product platform:
Our Products are referred here as the ‘nanomedicine’ according to their unique biophysical and biological features. Our APIs are formulated with our novel polymer excipient to synthetic ‘pathogen-like’ nanoparticles. The nanomedicine formulation is essential to achieve potent antigen expression from the pDNA and antigen presentation by dendritic cells. This is critical for the intensification of antigen-specific immune responses in people with chronic diseases.
3.DermaPrep – our topical administration platform:
We have developed DermaPrep medical device for targeted in vivo delivery of our nanomedicine Products to the dendritic cells of the lymph nodes via the Langerhans cells. We obtained the Marketing Approval in the European Union (CE Mark) for our DermaPrep device.
4.IT – Applied information technology:
IT innovations have been supporting the discovery, development, manufacturing, and personalized treatment processes of Genetic Immunity. These include the rational antigen design, clinical trial and data management and matching the patients with the optimal Immune Therapy Product.
Genetic Immunity has been founded in 1998. What drove you to set up the company at that time? J.L: To understand the context better, I first need to give a…
MD Pál Szamosújvari, Judit Jávor, Pál Szamosújvari Jr—Founder, R&D Director, and Director of Pharma Patent respectively—share their insights on the activities of the company, the importance of R&D, the challenges…
Csilla Léka, general manager of Global Clinical Trials in Hungary shares her insights on the portfolio of the company, the most prevalent therapeutic areas, the developments in clinical trials over…
Calin Galaseanu, recently appointed general manager of Novo Nordisk Hungary, elaborates on the country’s strong treatment paradigm for diabetes. He goes on to highlight Hungary’s key positioning as a strategic…
László Dene, managing director of Bellis, gives his insights on the trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company as the…
Gergely Jánoki CEO of Medi-Radiopharma shares his insights on the activities of the company, the trends in the radiopharmaceutical industry while highlighting regulatory trends, the importance of quality, the driving…
Dr Antal Feller, CEO of Hungaropharma, gives his insights on the pharma trends affecting the wholesale supply chain and product delivery in Hungary, the strategic positioning of the company, on…
Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in…
Dr. Bodoky Gyorgy, founder and Honorary President of the Hungarian Society of Clinical Oncology (MKOT), explains the activities of the society, the multi-stakeholder collaborations MKOT has, the challenges of oncological…
Péter Ferdinandy and Zsuzsanna Helyes, President and Secretary General of the Hungarian Society for Experimental and Clinical Pharmacology (HUPHAR), share their insights about the role of the society, the R&D…
József Béres, President of Béres and Ferenc Major, CEO, share their insights on the history of the company, its performance and approach to creating brand awareness, the importance of R&D…
Dr. András Szabó, CEO of Szinapszis, a Hungarian market research and consulting agency specialized in the health industry, offers his expert insights on the key challenges and trends shaping the…
After years of planning and collaboration with various stakeholders, in 2017 the Hungarian government launched the Electronic Health Service Area (EESZT): a centralized database of patient records and health interventions…
See our Cookie Privacy Policy Here